statistiche ricercatore

Continente	#
NA - Nord America	3.379
AS - Asia	289
EU - Europa	285
SA - Sud America	55
OC - Oceania	8
AF - Africa	4
Continente sconosciuto - Info sul continente non disponibili	1
Totale	4.021

Nazione	#
US - Stati Uniti d'America	3.372
SG - Singapore	115
CN - Cina	91
UA - Ucraina	55
BR - Brasile	44
RU - Federazione Russa	38
DE - Germania	34
FR - Francia	29
IE - Irlanda	28
IT - Italia	24
GB - Regno Unito	20
PL - Polonia	20
VN - Vietnam	19
FI - Finlandia	17
JP - Giappone	15
HK - Hong Kong	13
KR - Corea	10
SE - Svezia	9
AU - Australia	7
AR - Argentina	5
AT - Austria	4
CA - Canada	4
CO - Colombia	3
ID - Indonesia	3
IN - India	3
NL - Olanda	3
TW - Taiwan	3
BD - Bangladesh	2
ES - Italia	2
KZ - Kazakistan	2
MX - Messico	2
PK - Pakistan	2
TH - Thailandia	2
UZ - Uzbekistan	2
ZA - Sudafrica	2
A2 - ???statistics.table.value.countryCode.A2???	1
AE - Emirati Arabi Uniti	1
BO - Bolivia	1
BW - Botswana	1
CL - Cile	1
CR - Costa Rica	1
EC - Ecuador	1
EE - Estonia	1
IL - Israele	1
LT - Lituania	1
MA - Marocco	1
MY - Malesia	1
NZ - Nuova Zelanda	1
OM - Oman	1
PS - Palestinian Territory	1
SA - Arabia Saudita	1
TR - Turchia	1
Totale	4.021

Nome	#
Umeclidinium for the treatment of chronic obstructive pulmonary disease	445
The effect of indacaterol during an acute exacerbation of COPD	423
Translational study searching for synergy between glycopyrronium and indacaterol	419
A pilot comparison of helium dilution and plethysmographic lung volumes to assess the impact of a long-acting bronchodilator on lung hyperinflation in COPD	418
Chronic treatment with indacaterol and airway response to salbutamol in stable COPD	417
Comorbidities of asthma	415
Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi	413
Defining Phenotypes in COPD: An Aid to Personalized Healthcare	412
The clinical use of regenerative therapy in COPD	384
Omalizumab: stepping outside our comfort zone to broaden the number of those who can benefit	153
New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol	130
Totale	4.029

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	25	0	0	0	0	0	0	0	0	0	0	21	4
2021/2022	98	8	12	1	5	3	9	5	7	9	8	5	26
2022/2023	189	22	23	7	18	20	36	8	27	20	0	4	4
2023/2024	38	10	3	2	0	3	16	0	1	0	0	2	1
2024/2025	177	10	44	18	10	11	10	12	5	15	21	11	10
2025/2026	390	28	22	63	64	26	16	51	43	58	18	1	0
Totale													4.029